Longeveron LGVN 深 沪
等待开盘 07-09 09:30:00 美东时间
0.643
+0.011
+1.71%
华盛通- 最 高0.66
- 今 开0.639
- 成交量 10.31万股
- 最 低 0.6201
- 昨 收 0.6322
- 总市值 2031.75万
- 52周最高 1.80
- 市盈率 静 --
- 换手率 0.33%
- 52周最低 0.475
- 委 比 97.53%
- 总股本 3159.80万
- 历史最高 450.00
- 量 比 0.21
- 振 幅 6.31%
- 历史最低 0.475
- 每 手 1
- 风险率 0.28%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Longeveron grants special equity awards to Executive Chairman
Longeveron ( ($LGVN) ) has shared an announcement. On July 6, 2026, Longeveron,...
今天 04:31
Longeveron strengthens financial leadership with new CFO appointment
Longeveron ( ($LGVN) ) has issued an update. Longeveron Inc., a clinical-stage ...
07-07 05:27
Longeveron Names Marie Washburn as Chief Financial Officer Effective On July 13; Lisa Locklear To Step Down As CFO
Longeveron Inc. (NASDAQ:LGVN) a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company has appointed Marie Washburn to the Company’s executive leadership team in the role of Senior V...
07-07 04:08
Longeveron® Appoints Marie Washburn as Chief Financial Officer
Longeveron Inc. appoints Marie Washburn as Senior Vice President and Chief Financial Officer, effective July 13, 2026. With over 20 years of leadership experience in the pharmaceutical and biotech sectors, Washburn previously served as Vice President and Corporate Controller at the company. Her appointment comes as Longeveron anticipates top-line results from its Phase 2b clinical trial for laromestrocel in treating Hypoplastic Left Heart Syndrom...
07-06 20:05
New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer’s Disease Accepted for Poster Presentation at the 2026 Alzheimer’s Association International Conference (AAIC)
Longeveron Inc. announced that additional analysis from its Phase 2a clinical trial of laromestrocel for mild Alzheimer’s disease has been accepted for a poster presentation at the 2026 Alzheimer’s Association International Conference in London. The presentation will occur on July 13, 2026, during the In-Person Posters session. Results from the CLEAR MIND trial were previously published in *Nature Medicine* in March 2025, supporting laromestrocel...
06-18 13:20
Longeveron Granted Small Or Medium-Sized Enterprise Status By European Medicines Agency
According to the EMA, SME Designation has allowed for improved success rate for organizations seeking regulatory approvals:the success rate for SME marketing authorization applications for human medicines more than
06-09 21:21
Longeveron CFO Lisa Locklear Plans To Step Down, Effective July 10
https://www.sec.gov/ix?doc=/Archives/edgar/data/1721484/000121390026065788/ea0293758-8k_longeveron.htm
06-06 04:04
Longeveron to Present at BIO International Convention 2026
Longeveron Inc. will participate in the BIO International Convention 2026 to present its stem cell therapy laromestrocel, focusing on potential partnerships for Hypoplastic Left Heart Syndrome, Alzheimer’s disease, Pediatric Dilated Cardiomyopathy, and Aging-related Frailty. The company aims to leverage strategic collaborations to accelerate development and commercialization, with laromestrocel showing positive results across multiple clinical tr...
06-04 13:15
Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities
Longeveron Inc. CEO Stephen Willard outlines the company's strategic repositioning to maximize stockholder value and focuses on its stem cell therapy, laromestrocel, for life-threatening conditions. Key priorities include advancing the Phase 2b HLHS trial with expected data in August 2026, expanding into PDCM, and pursuing partnerships for Alzheimer’s disease and aging-related frailty. The company has secured new investments and aims to leverage ...
05-20 20:05
电话会总结 ｜ Longeveron(LGVN)2026财年Q1业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Longeveron业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** 2026年第一季度总营收40万美元，与2025年同期持平。其中临床试验收入40万美元，合同制造收入2万美元。 **亏损情况：** 净亏损470万美元，较2025年同期的500万美元减少30万美元。 **费用控制：** 一般管理费用270万美元，研发费用230万美元，两项费用均实现同比下降。 **现金状况：** 截至2026年3月31日，现金及现金等价物余额1,580万美元。 ## 2. 财务指标变化 **营收结构变化：** - 临床试验收入同比增长
05-14 12:24
